Phase 1 clinical trial by nebulization

    NEBUFLAG – A first-in-man phase 1 trial for nebulization of flagellin to treat respiratory infections.

    The Objectives of the NEBUFLAG study are:

    • To investigate the clinical safety/tolerability of a single dose of nebulized flagellin administered via the Aerogen® Solo nebulizer in spontaneously breathing healthy volunteers.
    • To obtain the first evidence of local immune-enhancing effect of nebulized flagellin in human.

    Copyright © 2024 - FAIR - All Rights Reserved.